| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5c121269689cbab9b3a4548b15caf3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 |
| filingDate |
2018-06-29^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12bca213624cc6b0a62509e8997b9fec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b50f31eba7456acce22019d533f71aef |
| publicationDate |
2020-02-18^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110809628-A |
| titleOfInvention |
A method for predicting the effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood T cells as an indicator |
| abstract |
The object of the present invention is to provide a companion diagnostic for predicting the effect of tumor immunotherapy. The effect of tumor immunotherapy is predicted by a method comprising the following steps: step 1: contacting peripheral blood mononuclear cells collected from a patient who is the object of malignancy treatment with tumor cells directly or indirectly in vitro; step 2: determining in step 2 Whether the tumor cells that have been in contact with the peripheral blood mononuclear cells in step 1 are damaged; and step 3: when it is determined in step 2 that the tumor cells have been damaged, it is determined that the tumor immunotherapy is effective against the malignant tumor in the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113125751-A |
| priorityDate |
2017-06-30^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |